Oslo, Norway, 1 June 2026. Reference is made to the stock exchange announcement
published 29 May 2026 by EXACT Therapeutics AS (the "Company", Euronext Growth
ticker: EXTX), a clinical-stage precision medicine company, announcing that the
Board proposes a delisting of the Company's ordinary shares, which are currently
listed on Euronext Growth Oslo.
In connection with the Board's proposal to delist the Company's shares from
Euronext Growth Oslo, The Company will host a webcast (in English) on Thursday,
4 June 2026, at 9:30 AM CET.
The presentation will be held by the Chair of the Board, Anders Wold; the
Company's CEO, Per Walday; and CFO, John M. Edminson.
There will also be a Q&A session after the presentation.
Link for registration for webcast: https://qcnl.tv/p/bF-lWKfBWtq-RNI9U1RcNw
The link will also be available on the Company homepage: www.exact-tx.com
About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound to activate the proprietary drug PS101 and enhance the
clinical benefit of oncology therapies. PS101 has a unique mode of action and
may be combined with a wide range of therapeutic agents within oncology and
across a multitude of other indications, including brain diseases. EXACT
Therapeutics' shares are traded on Euronext Growth Oslo (EXTX). Further
information may be found here: www.exact-tx.com
For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com
ACT Therapeutics\
Email: per.walday@exact-tx.com\